VALIUM
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VALIUM by Roche is clinical pharmacology diazepam is a benzodiazepine that exerts anxiolytic, sedative, muscle-relaxant, anticonvulsant and amnestic effects. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety. First approved in 1966.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALIUM is an injectable small-molecule benzodiazepine approved in 1966 for acute anxiety, muscle spasms, seizure management, and procedural sedation. The drug works by enhancing GABAergic neurotransmission in the central nervous system. It remains a foundational agent in acute care and anesthesia settings.
LOE Approaching
As a mature, approaching-LOE product with moderate competitive pressure, the team is likely focused on defending market position and managing transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Diazepam is a benzodiazepine that exerts anxiolytic, sedative, muscle-relaxant, anticonvulsant and amnestic effects. Most of these effects are thought to result from a facilitation of the action of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter in the central…
Worked on VALIUM at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.